Oncology

#AI / data analytics / healthtech / informatics #Cancer research #Collaboration #Drug development #Drug discovery #Oncology #Partnership

This week in drug discovery (13-17 February)

News round-up for 13-17 February by DDW Digital Content Editor Diana Spencer.  The drug discovery sector is feeling the love this Valentine’s week, with several new research collaborations bringing together a range of expertise and advanced bioinformatics, automation and artificial intelligence technologies to speed up the development of… Read More

#News

Testing visual acuity
#Aura Biosciences #Cancer research #Melanoma #Oncology #Ophthalmology #Phase II trial

Choroidal melanoma drug preserved vision in Phase II study

Aura Biosciences has announced positive interim Phase II safety and efficacy data for belzupacap sarotalocan (bel-sar) as a first-line treatment for patients with early-stage choroidal melanoma with suprachoroidal administration.  The results showed a statistically significant reduction in tumour growth rate compared to each patient’s documented growth rate… Read More

#Cancer Research #News

Big genomic data
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Bioinformatics #Collaboration #Genetics / genomics #Oncology #Partnership

Partners hope to “chart a new era of drug discovery”

A new multi-year strategic partnership between M2GEN and Zephyr AI will leverage clinicogenomic data, bioinformatics, and artificial intelligence to accelerate drug discovery and expanded use cases for oncology treatments.  In this partnership, M2GEN will license its real-world data set (RWD) to Zephyr AI, while Zephyr AI will… Read More

#Cancer Research #News

#Assay development optimisation & technology #Cancer immunotherapy #Cancer research #Immuno-oncology #Immunotherapy #Oncology

The evolution of assays for immuno-oncology research

Listen to this article on the DDW Podcast: By Dr Shailendra Singh, founder and CEO of Cellomatics Biosciences. Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was… Read More

#Cancer Research #Exclusive Content

Tumour microenvironment
#Absci #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer research #Oncology #St John’s Cancer Institute #Tumours

Partners use AI to speed up development of cancer therapies

AI company Absci and St John’s Cancer Institute (SJCI) have entered a partnership to uncover breakthrough cancer therapies.   The companies will use Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to identify new… Read More

#Cancer Research #News

Endometrial biopsy
#Cancer research #FDA #GSK #Immuno-oncology #Oncology #Phase I trial #Regulatory

Full FDA approval for endometrial cancer treatment

The US Food and Drug Administration (FDA) has granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test.  The approval is for endometrial cancer that has progressed on or… Read More

#News #Regulatory

#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Drug development #Drug discovery #Oncology #Phase III trial

This week in drug discovery (6-10 February)

News round-up for 6-10 February by DDW Digital Content Editor Diana Spencer.  Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient… Read More

#News

Patient having a mammogram
#Breast cancer #Cancer research #Clinical research #Clinical trials #Oncology #Phase II trial

Breast cancer still top disease area for clinical studies

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, despite a drop in activity, according to analysis from analytics company Phesi.  The company’s global analysis of all clinical trials conducted in 2022 showed that Covid-19 came second.   Three of… Read More

#Cancer Research #News

Stamp of approval
#AstraZeneca #Cancer #Chemotherapy #Clinical research #MHRA #Oncology

First-line AZ treatment for adults with biliary tract cancer approved 

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC).1 This authorisation by… Read More

#Cancer Research #News

#Breast cancer #Cancer research #CAR-T #Drug development #Drug discovery #Immuno-oncology #Lung cancer #Oncology #World Cancer Day

The DDW Highlights Podcast: World Cancer Day 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As 4 February was World Cancer Day, this week’s update focused on… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug development #Drug discovery #Immuno-oncology #Lung cancer #Oncology #World Cancer Day

This week in drug discovery (30 January – 3 February)

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer.  As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will … Read More

#News

Cancer cells
#Breast cancer #Cancer research #FDA #Gene mutation #Genetics / genomics #Menarini #Oncology #Stemline Therapeutics

FDA-approved therapy targets ESR1 mutations in breast cancer

The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US.  The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+,… Read More

#News #Regulatory

Glasgow, Scotland
#Cancer treatment #Health inequalities #Oncology #Personalised medicine #Precision medicine #University of Glasgow

Commission tackles global access to precision cancer treatments

A team of experts from the University of Glasgow will lead a new international effort to improve cancer control and reduce global health inequalities.  Spearheading the new Lancet Oncology Commission focused on cancer genomics and precision oncology, Glasgow researchers will lead an international team of experts over… Read More

#News

#Anti-inflammatory #Cancer research #EpicentRx #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

RRx-001: Jack of all trades, master of…many

Listen to this article on the DDW podcast: Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. Introduction The term “dilettante”, at least in English, connotes a sloppy bungler, a smatterer, a… Read More

#Exclusive Content

Growing bacteria to create CAR therapy
#Cancer research #CAR-T #Immuno-oncology #Immunotherapy #Kite Pharma #National Institute for Health and Care Excellence (NICE) #NHS England #Oncology #UK

Ground-breaking CAR-T therapy approved in UK

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)… Read More

#News #Regulatory #Trending News